Insights on the Digital Therapeutics Global Market to 2027 - by Application, End-use and Region - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Digital Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global digital therapeutics market reached a value of US$ 4.2 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 13.4 Billion by 2027, exhibiting a CAGR of 21.33% during 2021-2027.
- 2Morrow Inc.
- Canary Health Inc.
- Click Therapeutics Inc.
- Mango Health Inc. (TrialCard Incorporated)
- Noom Health Inc.
- Omada Health Inc.
- Pear Therapeutics Inc.
- Propeller Health (ResMed)
- Teladoc Health Inc.
- Voluntis Inc.
- WellDoc Inc.
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients. They aid in enhancing the existing medical treatments, providing therapy solutions, and reducing reliance on pharmaceuticals using high-quality software programs.
They also prevent, manage and treat physical, mental, and behavioral health and find application in diagnosing conditions like Alzheimer's disease, type II diabetes, and respiratory disorders, such as asthma, gastrointestinal problems, and chronic obstructive pulmonary disease. At present, there is a significant rise in the demand for DTx as they reduce health care costs and support the overall health of patients.
The boosting sales of smart devices like mobile phones and tablets, rising internet penetration and the increasing number of healthcare applications are among the major factors strengthening the growth of the market. DTx finds application in a diverse range of neuroscience indications, such as autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), depression, schizophrenia, and bipolar disease.
Additionally, the rising prevalence of chronic diseases like diabetes and obesity, along with the increasing need for controlling costs of healthcare treatments, are supporting the growth of the market. Furthermore, pharmaceutical companies around the world are investing and engaging in strategic partnerships to expand their product portfolio and market reach.
They are also focusing on providing patients with information concerning different conditions and subsequent treatments as well as organizing, tracking, and self-managing their diseases. These initiatives undertaken by pharmaceutical companies are anticipated to impel the growth of the market.
Key Questions Answered in This Report
1. What was the size of the global digital therapeutics market in 2021?
2. What is the expected growth rate of the global digital therapeutics market during 2022-2027?
3. What are the key factors driving the global digital therapeutics market?
4. What has been the impact of COVID-19 on the global digital therapeutics market?
5. What is the breakup of the global digital therapeutics market based on the application?
6. What is the breakup of the global digital therapeutics market based on the end use?
7. What are the key regions in the global digital therapeutics market?
8. Who are the key players/companies in the global digital therapeutics market?
Key Topics Covered:
2 Scope and Methodology
3 Executive Summary
4.2 Key Industry Trends
5 Global Digital Therapeutics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Application
7 Market Breakup by End Use
8 Market Breakup by Region
9 SWOT Analysis
10 Value Chain Analysis
11 Porters Five Forces Analysis
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
For more information about this report visit https://www.researchandmarkets.com/r/xw71rn
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900